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A randomized placebo-controlled phase 
II study of clarithromycin or placebo combined 
with VCD induction therapy prior to high-dose 
melphalan with stem cell support in patients 
with newly diagnosed multiple myeloma
Henrik Gregersen1* , Trung Do2, Ida Bruun Kristensen3, Ulf Christian Frølund4, Niels Frost Andersen5, 
Lene Kongsgaard Nielsen6, Christen Lykkegaard Andersen4, Tobias Wirenfeldt Klausen2, 
Annette Juul Vangsted7† and Niels Abildgaard8†
Abstract 
Background: The objective of this randomized placebo-controlled study was to investigate the efficacy and safety 
of clarithromycin in combination with bortezomib–cyclophosphamide–dexamethasone (VCD) in patients with newly 
diagnosed multiple myeloma eligible for high-dose therapy.
Methods: Patients were randomized to receive tablet clarithromycin 500 mg or matching placebo tablet twice daily 
during the first 3 cycles of VCD induction therapy. Primary endpoint was to compare the rate of very good partial 
response (VGPR) or better response after three cycles of VCD combined with clarithromycin or placebo.
Results: The study was prematurely stopped for safety reasons after the inclusion of 58 patients (36% of the planned 
study population). The patients were randomly assigned to clarithromycin (n = 27) or placebo (n = 31). VGPR or better 
response after the VCD induction therapy was obtained in 12 patients (44.4%, 95% CI 25.5–64.7) and in 16 patients 
(51.6%, 33.1–69.8) (p = 0.59) in the clarithromycin group and the placebo group, respectively. Seven patients (25.9%) 
in the clarithromycin group developed severe gastrointestinal complications (≥ grade 3) comprising pain, neutro-
penic enterocolitis, paralytic ileus or peptic ulcer. These complications occurred in only one patient in the placebo 
group. Septicemia with Gram negative bacteria was observed in 5 patients in the clarithromycin group in contrast to 
one case of pneumococcal septicemia in the placebo group. Patient-reported QoL were negatively affected in the 
clarithromycin group compared to the placebo group.
Conclusion: The study was prematurely stopped due to serious adverse events, in particular serious gastrointestinal 
complications and septicemia. The response data do not suggest any effect of clarithromycin when added to the VCD 
regimen. The combination of clarithromycin and bortezomib containing regimens is toxic and do not seem to offer 
extra anti-myeloma efficacy.
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Background
Clarithromycin has been proposed as a potentially 
good candidate for addition to multiple myeloma ther-
apy in pursuit of synergistic effects [1]. This concept is 
based on the favorable toxicity profile of clarithromycin 
when used in the treatment of infections, the very low 
cost and response data from combination with immu-
nomodulatory drugs (IMiDs) in phase II trials and 
in one case-matched study [2–5]. In a study by Nies-
vizky et al. the combination of clarithromycin, 500 mg 
twice daily with lenalidomide and dexamethasone led 
to partial response or better in 90% of treatment-naive 
patients with symptomatic multiple myeloma [4]. Gay 
et  al. conducted a case-matched analysis based on the 
Niesvizky study and compared 72 patients treated with 
clarithromycin, lenalidomide and dexamethasone with 
an equal number of patients seen at the Mayo Clinic 
only treated with lenalidomide and dexamethasone [5]. 
The study indicated a very favorable effect of clarithro-
mycin with a higher frequency of complete response 
(CR), and very good partial response (VGPR) or better 
in the clarithromycin group. In addition, time-to-pro-
gression and progression-free survival were longer in 
the clarithromycin group. However, there are so far no 
data from randomized controlled studies to support an 
effect of clarithromycin in multiple myeloma.
Cellular studies have shown that clarithromycin 
attenuates autophagy in myeloma cells at clinically rele-
vant concentrations (6–50 μg/mL) [6]. The combination 
of clarithromycin and bortezomib results in increased 
cytotoxicity compared to bortezomib alone in myeloma 
cell lines [7]. A possible mechanism underlying this 
synergistic effect might be simultaneous inhibition of 
the ubiquitin–proteasome system by bortezomib and 
the autophagy-lysosome system by clarithromycin 
resulting in over-loading endoplasmic reticulum-stress 
in myeloma cells [7]. However, it is unknown whether 
this observation could be translated into clinical effi-
cacy in treatment of multiple myeloma patients.
The Danish Myeloma Study Group (DMSG) there-
fore initiated a randomized, double-blind, placebo-con-
trolled phase 2 study to evaluate the efficacy and safety 
of adding clarithromycin to the bortezomib-containing 
triplet induction regimen bortezomib–cyclophospha-
mide–dexamethasone (VCD) in multiple myeloma 
patients eligible for high-dose melphalan with stem cell 
support (HDT).
Methods
Trial design
This randomized, double-blind, placebo-controlled 
phase II study was designed and conducted by the Dan-
ish Myeloma Study Group (DMSG). It included mul-
tiple myeloma patients from six Danish sites and was 
planned to include a total of 160 patients. The study was 
approved Danish Health and Medicines Authority (No. 
2014061645) and Danish Data Protection Agency (No. 
2008-58-0028). EudraCT and ClinicalTrials.gov Numbers 
are 2014-002187-32 and NCT02573935, respectively. 
Independent monitors from the Danish Good Clinical 
Practice units in Copenhagen, Aarhus and Odense car-
ried out the monitoring.
Patients
The study included patients with newly diagnosed 
multiple myeloma with treatment demanding disease 
according to the International Myeloma Working Group 
(IMWG) criteria [8]. Only patients eligible for high-dose 
melphalan with stem cell support were included. The key 
exclusion criteria were any given anti-myeloma treatment 
prior to inclusion, except radiotherapy, bisphosphonates/
denosumab or corticosteroids for symptom control, pro-
longed QT corrected (QTc) interval (> 500 ms on screen-
ing ECG), uncontrolled or severe cardiovascular disease, 
severe renal dysfunction (estimated creatinine clear-
ance < 10  mL/min) and concurrent treatment with cer-
tain potentially interacting medications, e.g. fluconazole, 
verapamil and simvastatin.
Trial treatment
Patients were randomized (1:1 ratio) to receive oral 
clarithromycin 500  mg or a matching placebo tablet 
twice daily during the first 3 cycles of VCD induction 
therapy. The randomization was stratified according 
to International Staging System stage (1, 2 or 3). The 
VCD consisted of 21-day cycles of subcutaneous bort-
ezomib 1.3  mg/sqm days 1, 4, 8, 11, intravenous cyclo-
phosphamide 500  mg/sqm on days 1 and 8, and oral 
dexamethasone 40  mg  days 1, 2, 4, 5, 8, 9, 11, 12. The 
number of VCD series was changed from three to four 
Trial registration EudraCT (no. 2014-002187-32, registered 7 October 2014, https ://www.clini caltr ialsr egist er.eu/ctr-
searc h/trial /2014-00218 7-32/DK) and ClinicalTrials.gov (no NCT02573935, retrospectively registered 12 October 2015, 
https ://www.clini caltr ials.gov/ct2/show/NCT02 57393 5?term=Grege rsen&cntry =DK&rank=9)
Keywords: Multiple myeloma, Clarithromycin, Bortezomib, Adverse drug event, Induction chemotherapy, Double 
blind study
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in the national Danish guidelines for treatment of multi-
ple myeloma during conduct of the study. Consequently, 
after a protocol amendment the induction therapy was 
changed to four series of VCD but the treatment dura-
tion of clarithromycin or placebo was unchanged. After 
the induction therapy the patients proceeded to cyclo-
phosphamide priming (2000  mg/sqm), peripheral blood 
stem cell harvest by leukapheresis and high-dose melpha-
lan (200 mg/sqm) with stem cell support.
End‑points and assessments
The primary end-point of the study was to compare the 
rate of very good partial response or better response 
(≥ VGPR) after three courses of VCD combined with 
clarithromycin or placebo. The response was assessed 
according to the International Myeloma Working Group 
criteria for response in multiple myeloma [9]. An impor-
tant secondary end-point was to compare the rate of 
≥ VGPR 2 months after high-dose melphalan with stem 
cell support. Other secondary end-points included the 
frequency of infections and the number of stem cells har-
vested in patients in the two treatment groups. Patient-
reported quality of life (QoL) and neurotoxicity were 
secondary end-points, and assessed at inclusion and 
after 2 and 6  months. Two European Organisation for 
Research and Treatment of Cancer QoL (EORTC) ques-
tionnaires were used; EORTC QLQ-C30 and the Multiple 
Myeloma module EORTC QLQ-MY20 [10, 11]. Neuro-
toxicity was assessed by the Functional Assessment of 
Cancer Therapy/Gynecologic Oncology Group-Neuro-
toxicity (FACT/GOG-Ntx) subscale questionnaire [12]. 
Analyses were by intention-to-treat.
Safety assessment
Adverse events were graded according to National Can-
cer Institute Common Toxicity Criteria (NCI CTC) Ver-
sion 4.0.
Unblinding
Unblinding of study drug status of the individual patient 
was performed after final study evaluation 2 months after 
HDT provided that all CRFs had been completed and 
approved by the study office. This approach was used to 
allow for participation in other myeloma studies or the 
use of tandem transplantation in selected patients.
Statistical analysis
Comparisons of binary variables were conducted by 
Fisher’s exact test, mid-P approach as appropriate. Dif-
ferences in primary endpoints between treatment arms 
were presented using absolute risk difference with 95% 
confidence intervals (95% CI). Continuous variables were 
presented using medians with range or interquartile 
range. Continuous and ordinal variables were compared 
using Mann–Whitney test except for patient related 
outcomes. For analyzing time to exclusion the Kaplan–
Meier method was used and differences between treat-
ment arms were compared using the Log-rank test. 
Differences of patient related outcomes between groups 
were adjusted for baseline measures and analyzed using a 
constrained longitudinal data analysis (cLDA) estimated 
by a mixed model using unstructured covariance [13]. 
All confidence intervals are 95% and all confidence inter-
vals and p-values are two-sided. Data analyses were per-
formed using R version 3.3.3 (R Foundation for Statistical 
Computing, Vienna, Austria) except for mixed models 
which were performed using SAS version 9.4 (SAS insti-
tute, Cary, SC, USA).
Results
The study was prematurely stopped by the study safety 
board for safety reasons after inclusion of 58 patients 
(36% of the planned study population). The median age 
of included patients was 63  years (interquartile range 
55–66  years). Twenty-seven patients were assigned to 
clarithromycin treatment and 31 to placebo. The clinical 
characteristics at baseline are described in Table 1.
Efficacy
The primary end-point VGPR or better response after 
the VCD induction therapy was obtained in 12 patients 
(44.4%, 95% CI 25.5–64.7%) and in 16 patients (51.6%, 
33.1–69.8%) (p = 0.59) in the clarithromycin group and 
the placebo group, respectively. There were no differ-
ences between the two groups for any of the secondary 
endpoints VGPR or better response 2 months after high-
dose melphalan with stem cell support, yield of harvested 
stem cells and number of infections (Table 2).
Safety
Most patients in the clarithromycin group and the pla-
cebo group had at least one adverse event during the 
VCD induction therapy (96.3% and 90.3%, respectively) 
(Table 3). The most common adverse events of any grade 
are summarized in Table  4. Frequent adverse events in 
the clarithromycin group were thrombocytopenia, sep-
ticemia, oral candidiasis, peripheral sensory neuropa-
thy (p = 0.03), dizziness, peripheral edema, hypotension 
and various psychiatric symptoms. By contrast, the 
occurrence of respiratory tract infection was low in the 
clarithromycin group.
A total of 26 serious adverse events (SAEs) were 
reported in 16 (59.3%) patients in the clarithromycin 
group and 16 SAEs in 10 (32.3%) patients in the pla-
cebo group. A large fraction of the SAEs was constituted 
by gastrointestinal complaints with associated serious 
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complications which were seen in 7 (25.9%) patients in 
the clarithromycin group and in 1 patient (3.2%) in the 
placebo group. A common complication in patients with 
gastrointestinal complaints in the clarithromycin group 
was septicemia which was detected in 5 cases and consti-
tuted well-known gastrointestinal bacteria. By contrast, 
the only case of septicemia detected in the placebo group 
was pneumococcal sepsis associated with pneumonia. 
There was one death in the clarithromycin group (duode-
nal ulcer) and one death in the control group (perforated 
diverticulitis). As a consequence of the imbalance in gas-
trointestinal symptoms and septicemia the study safety 
board decided to terminate inclusion of new patients and 
administration of the study drug ceased on 16 September 
Table 1 Baseline characteristics of patients
IQR interquartile range, LDH lactate dehydrogenase
a t(4;14), t(14;16), t(14;20) or del(17p)
Clarithromycin group (N = 27) Placebo group (N = 31)
Variable
 Age (years) Median (IQR) 63 (55.0–66.5) 63 (55.5–66.0)
 Male sex No. (%) 20 (74.1%) 20 (64.5%)
 Type of myeloma No. (%)
  IgA 3 (11.1%) 9 (29.0%)
  IgG 20 (74.1%) 17 (54.8%)
  Light chain 4 (14.8%) 5 (16.1%)
 International staging system No. (%)
  I 7 (%) (25.9%) 9 (29.0%)
  II 10 (%) (37.0%) 17 (54.8%)
  III 9 (33.1%) 4 (12.9%)
  Missing 1 (3.8%) 1 (3.2%)
 Cytogenetic features No. (%)
  Standard risk 18 (66.7%) 18 (58.1%)
  High  riska 6 (22.2%) 8 (25.8%)
  Data not available 3 (11.1%) 5 (16.1%)
 WHO performance status No. (%)
  0 14 (51.9%) 17 (54.8%)
  ≥ 1 13 (48.1%) 14 (45.2%)
 Serum creatinine ≥ 130 µmol/L No. (%) 5 (18.5%) 2 (6.5%)
 Serum LDH ≥ 260 U/L No. (%) 1 (3.7%) 4 (12.9%)
 Serum C-reactive protein ≥ 8 mg/L No. (%) 9 (33.3%) 9 (29.0%)
Table 2 Clinical outcomes
VGPR very good partial response, HDT high-dose melphalan with hematopoietic stem cell support
a Not significant (Fisher’s exact test)
b Not significant (Mann–Whitney test)
c Pclarithromycin − Pcontrol For response negative numbers indicate lower response in clarithromycin group. For infection positive number indicates higher risk of infection 
in clarithromycin group
Clarithromycin group (N = 27) Placebo group (N = 31) Pclarithromycin − Pcontrol
Clinical outcomes
 VGPR or better 
response after VCD 
induction
No. (%, 95% CI) 12 (44.4%, 25.5–64.7%) 16 (51.6%, 33.1–69.8%)a − 7.2% (− 30.7–
17.6%)c
 VGPR or better 
response after HDT
No. (%, 95% CI) 16 (59.3%, 38.8–77.6%) 23 (74.2%, 55.4–88.1%)a − 14.9% (− 37.1–
8.9%)c
 Leukapheresis 106/kg (range) 8 (2–20) 8.5 (2–18)b –
 Any infection No. (%, 95% CI) 16 (59.3%, 38.8–77.6%) 18 (58.1%, 39.1–75.5%)a 1.2% (− 23.0–24.9%)c
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2016. The VCD treatment and follow-up in the study 
continued.
Treatment
The fraction of patients who either had a reduced dose 
of study drug or discontinued study drug due to adverse 
events was higher in the clarithromycin group compared 
with the placebo group (33.3% and 9.7%, respectively). In 
addition, there was a trend towards more frequent reduc-
tion of VCD drug doses in the clarithromycin group 
compared with the placebo group, e.g. for bortezomib 
33.3% and 12.9%, respectively (Table 3).
Patient‑reported outcomes
Patients in the clarithromycin group reported more and 
clinical relevant neurotoxicity on the FACT/GOG-Ntx 
subscale and clinical relevant reduced global Qol on the 
EORTC QLQ C30 than patients in the placebo group 
after three VCD series. Two month after HDT there was 
still a mean score difference between the two treatment 
groups, but the differences were not clinical relevant any-
more (Fig. 1).
Discussion
To our knowledge, this study is the first randomized 
placebo-controlled trial examining the effect of adding 
clarithromycin to conventional myeloma therapy. The 
study was prematurely stopped for safety reasons, which 
affect the interpretation of the results, but our data do 
not suggest any anti-myeloma effect of clarithromycin 
when added to the VCD regimen.
The case-matched retrospective analysis by Gay et  al. 
found a very pronounced effect of adding clarithromycin 
to treatment with lenalidomide and dexamethasone, 
e.g. tripling of the CR rate [5]. The lack of efficacy of 
clarithromycin in combination with CVD in our study 
does not rule out a significant and clinical meaningful 
effect of clarithromycin in combination with other mye-
loma drugs, e.g. the immunomodulatory agents (IMiDs). 
The potential effect of the combination of clarithromycin 
and lenalidomide is to our knowledge currently being 
assessed in two active recruiting randomized controlled 
trials.
At the planning of our study a major concern was 
potential serious cardiac side effects since clarithro-
mycin may increase the QT interval, and the drug has 
been associated with risk of cardiovascular events and 
increased mortality in patients with stable coronary heart 
disease and in patients without heart disease [14, 15]. The 
exclusion criteria in our study were therefore strict in 
regard to previous cardiovascular disease and concomi-
tant use of drugs that might increase the QT interval. 
Maybe due to this, we did not encounter any serious car-
diovascular morbidity during conduct of the study.
Surprisingly, we observed an increased occurrence of 
several types of adverse events in patients who received 
clarithromycin in combination with VCD and several 
mechanisms may underlie this finding. First, bortezomib 
is metabolized by the cytochrome P450 (CYP) enzymes, 
and in particular the CYP3A4 is the major contributor 
to bortezomib metabolism [16]. Secondly, clarithromy-
cin inhibits CYP3A4 and probably the observed adverse 
events in our study were merely an effect of increased 
biological bortezomib exposure due to reduced metabo-
lism [17]. Peripheral neuropathy is a common adverse 
event during treatment with bortezomib and we found 
Table 3 Overall safety profile and drug doses in the clarithromycin group and placebo group
a p = 0.049 (Fisher’s exact test)
b Not significant (Fisher’s exact test)
Clarithromycin group, No = 27 Placebo group, No = 31
120/180 days follow-up—% 77.8% (63.6%; 95.2%) 90.3% (80.5%; 100%)
Treatment cycles—no. (%)
 1 1 (3.7%) 2 (6.4%)
 2 3 (11.1%) 1 (3.2%)
 3 16 (59.3%) 19 (61.2%)
 4 7 (25.9%) 9 (29.0%)
Any adverse event—no. (%) 26 (96.3%) 28 (90.3%)
Any ≥ 3 adverse event—no. (%) 16 (59.3%) 12 (38.7%)
Any serious adverse event—no. (%) 16 (59.3%) 10 (32.3%)
Adverse event resulting in dose reduction of study drug—no. (%) 9 (33.3%) 3 (9.7%)a
Adverse event resulting in dose reduction of bortezomib—no. (%) 9 (33.3%) 4 (12.9%)b
Adverse event resulting in dose reduction of dexamethasone—no. (%) 9 (33.3%) 3 (9.7%)a
Adverse event resulting in dose reduction of cyclophosphamide—no. (%) 4 (14.8%) 1 (3.2%)b
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a clear difference between the two treatment groups in 
our study [18]. In accordance with this observation an 
increased occurrence of peripheral neuropathy and also 
thrombocytopenia has been observed in patients who 
received concomitantly bortezomib and itraconazole, 
another potent CYP3A4 inhibitor [19]. Possibly, this 
mechanism might explain some of the observed gastro-
intestinal symptoms, e.g. increased occurrence of con-
stipation and paralytic ileus in our study. In addition, 
other factors might have contributed, e.g. clarithromy-
cin increases the pharmacologic effect of steroids and 
cases of pseudomembranous colitis have been observed 
in patients treated with clarithromycin as part of eradi-
cation therapy for Helicobacter pylori infection [4, 
20–22]. In accordance with our findings an increased 
rate of grade 3–4 adverse events was also observed in the 
clarithromycin group in the case-matched study by Gay 
et al. [5], and noteworthy three cases of perforated colon 
occurred in the clarithromycin group in contrast to none 
in the control group. However, the occurrence of septice-
mia was the same in the groups in the study by Gay et al. 
which is in contrast to our results [5]. Although most of 
the measures of safety in our study did not reach statis-
tical significance our data consistently suggest an unfa-
vorable pattern of clarithromycin combined with VCD 
on the number and degree of adverse events, on feasibil-
ity of the regimen and on the two patient-reported out-
comes quality of life and neurotoxicity. Such a pattern is 
Table 4 Most common adverse events in the clarithromycin and placebo group
The table included adverse event of any grade that occurred in more than 10% in any of the treatment groups or adverse events grade 3 or more that occurred in 
more than 5% in any of the treatment groups
a The group psychiatric symptoms encompass anxiety, agitation, depression and psychosis
Clarithromycin group, No = 27 Placebo group, No = 31
Any grade Grade 3 or 4 Any grade Grade 3 or 4
Hematologic events
 Thrombocytopenia 11 (40.7%) 2 (7.4%) 7 (22.6%) 0
 Anemia 12 (44.4%) 2 (7.4%) 11 (35.5%) 0
 Neutropenia 11 (40.7%) 1 (3.7%) 13 (41.9%) 0
Gastrointestinal events
 Typhlitis and perforation of colon 2 (7.4%) 2 (7.4%) 1 (3.2%) 1 (3.2%)
 Paralytic ileus 2 (7.4%) 2 (7.4%) 0 0
 Constipation 6 (22.2%) 1 (3.7%) 5 (16.1%) 0
 Diarrhea 4 (14.8%) 3 (11.1%) 5 (16.1%) 1 (3.2%)
 Dyspepsia 3 (11.1%) 0 1 (3.2%) 0
 Nausea 5 (18.5%) 0 6 (19.4%) 0
Infections
 Respiratory tract infection 5 (18.5%) 2 (7.4%) 8 (25.8%) 5 (16.1%)
 Urinary tract infection 3 (11.1%) 1 (3.7%) 5 (16.1%) 1 (3.2%)
 Septicemia 5 (18.5%) 5 (18.5%) 1 (3.2%) 1 (3.2%)
 Other infections 6 (22.2%) 4 (14.8%) 9 (29.0%) 5 (16.1)
 Oral candidiasis 7 (25.9%) 1 (3.7%) 1 (3.2%) 0
Nervous system disorders
 Peripheral sensory neuropathy 15 (55.6%) 0 8 (25.8%) 0
 Dizziness 4 (14.8%) 1 (3.7%) 3 (9.7%) 0
Other conditions
 Peripheral edema 11 (40.7%) 1 (3.7%) 7 (22.6%) 1 (3.2%)
 Hypotension 4 (14.8%) 2 (7.4%) 1 (3.2%) 0
 Fatigue 4 (14.8%) 1 (3.7%) 3 (9.7%) 0
 Rash 2 (7.4%) 0 4 (12.9%) 0
 Insomnia 2 (7.4%) 0 6 (19.4%) 0
 Weight loss 3 (11.1%) 0 1 (3.2%) 0
 Mucositis 2 (7.4%) 0 4 (12.9%) 0
 Psychiatric  symptomsa 5 (18.5%) 1 (3.7%) 2 (6.5%) 1 (3.2%)
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not acceptable in an era of novel potent anti-myeloma 
drugs with favorable safety profiles where in particu-
lar the monoclonal antibodies daratumumab and elo-
tuzumab are likely to constitute important elements of 
bortezomib-containing regimens [23, 24].
In conclusion, although we were only able to analyze 
response data in 58 included patients, our data do not 
indicate any additional effect of clarithromycin when 
added to the VCD regimen, and due to treatment toxic-
ity our trial does not encourage further clinical studies 
on the combination of clarithromycin and bortezomib. In 
patients treated with combined clarithromycin and VCD 
we observed an increased frequency of serious adverse 
events, in particular serious gastrointestinal compli-
cations and septicemia. This emphasizes the need for 
controlled studies on the efficacy of clarithromycin, both 
in assessment of potential anti-myeloma effects as well as 
for assessment of safety measures.
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